Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome (Q58415971)

21

Thierry Facon

0 references

Philippe Moreau

8

Philippe Moreau

0 references

Borhane Slama

16

Borhane Slama

0 references

Philippe Rodon

12

Philippe Rodon

0 references

Lotfi Benboubker

6

Lotfi Benboubker

0 references

Gerald Marit

5

Gérald Marit

0 references

Anne-Marie Stoppa

10

Anne-Marie Stoppa

0 references

Mamoun Dib

13

Mamoun Dib

0 references

Jean-Luc Harousseau

19

Jean-Luc Harousseau

0 references

Laurent Voillat

7

Laurent Voillat

0 references

Mohamad Mohty

20

Mohamad Mohty

0 references

Chantal Doyen

4

Chantal Doyen

0 references

Brigitte Pegourie

14

Brigitte Pegourie

0 references

Christian Berthou

9

Christian Berthou

0 references

Frederic Maloisel

11

Frédéric Maloisel

0 references

Philippe Casassus

15

Philippe Casassus

0 references

Robert Zerbib

18

Robert Zerbib

0 references

author name string

Jean-Yves Mary

2

0 references

Cyrille Hulin

3

0 references

Ghandi Damaj

European Journal of Haematology

17

0 references

publication date

4 January 2012

0 references

published in

0 references

volume

88

0 references

issue

3

0 references

page(s)

249-259

0 references

cites work

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Thalidomide for treatment of multiple myeloma: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

The future role of thalidomide in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Thalidomide: present and future in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Neuropathy in multiple myeloma treated with thalidomide: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

New developments and treatment in multiple myeloma: new drugs in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Thalidomide and dexamethasone combination for refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Low-dose thalidomide in myeloma: efficacy and biologic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Efficacy of a low dose of thalidomide in advanced multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Thalidomide and low-dose dexamethasone in myeloma treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Thalidomide and dexamethasone for resistant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

The current status of thalidomide in the management of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Development of effective new treatments for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01729.X